Patient-level, control-arm data from multiple aggregated studies of AD and MCI. The database contains, but is not limited to, demographic information, APOE4 genotype, concomitant medications, and cognitive scales (MMSE and ADAS-Cog). All data has been remapped to a common data standard such that all the data can be analyzed across all studies. It is available to CPAD consortium members, and to external qualified researchers who submit, and are approved for, a request for access. All data are fully de-identified. Data was originally mapped to SDTM and converted to a relational database.
To learn more, visit the Critical Path Institute’s overview of this data set here.
Manuscripts citing this dataset
- The Critical Path for Alzheimer’s Disease (CPAD) Consortium: A platform for pre-competitive data sharing, standardization, and analysis to support quantitative tools for AD drug development. 2021. DOI: https://doi.org/10.1002/alz.051903
- DRAFT Qualification opinion for Prognostic Covariate Adjustment (PROCOVA). 2022. https://www.ema.europa.eu/en/documents/other/draft-qualification-opinion-prognostic-covariate-adjustment-procovatm_en.pdf
- Effective Data Sharing as a Conduit for Advancing Medical Product Development. 2021. DOI: 1007/s43441-020-00255-8
- Open Data Revolution in Clinical Research: Opportunities and Challenges. DOI: https://doi.org/10.1111/cts.12756
- Technologies for Measuring Cognition in Clinical Trials. https://isctm.org/public_access/Autumn2018/Presentation/Arneric-Aut18.pdf
- Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments. 2018. DOI: https://doi.org/10.1016/j.bcp.2018.01.043
- Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease. A Meta-analysis. 2017. DOI: 1001/jamaneurol.2017.2188
- Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem. 2017. DOI: https://doi.org/10.1038/nrd.2017.153
Post a question or thought about this dataset here.